Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Clinical trial NCT04984876 · TERMINATED

Trial details

NCT number: NCT04984876
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Allergy, Peanut

Start date: 2021-12-07
Primary completion: 2023-11-27
Enrollment: 211

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.